

Survey of Virulence Determinants among Vancomycin Resistant *Enterococcus faecalis* and *Enterococcus faecium* Isolated from Clinical Specimens of Hospitalized Patients of North west of Iran

Yaeghob Sharifi^{1,2,6}, Alka Hasani^{1,2,*}, Reza Ghotaslou², Mojtaba Varshochi^{1,3}, Akbar Hasani^{1,4}, Mohammad Aghazadeh² and Morteza Milani^{2,5}

¹Research Center of Infectious Diseases and Tropical Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

²Department of Clinical Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

³Department of Infectious Diseases, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

⁴Department of Clinical Biochemistry and Biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran

⁵Faculty of Pharmacy, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

⁶Microbiology laboratory of Imam Khomeini Hospital, Orumieh University of Medical Sciences, Orumieh, Iran

Abstract: Recent data indicates an increasing rate of vancomycin resistance in clinical enterococcal isolates worldwide. The nosocomial enterococci are likely to harbor virulence elements that increase their ability to colonize hospitalized patients. The aim of this study was to characterize virulence determinants in vancomycin-resistant enterococci (VRE) obtained from various clinical sources.

During the years 2008 to 2010, a total of 48 VRE isolates were obtained from three University teaching hospitals in Northwest, Iran. Initially, phenotypic speciation was done and minimum inhibitory concentrations (MICs) of vancomycin were determined by agar dilution method and E-test. Then, species identification and resistance genotypes along with detection of virulence genes (*asa1*, *esp*, *gelE*, *ace* and *cpd*) of the isolates were performed by multiplex PCR.

Thirty eight isolates were identified as vancomycin-resistant *Enterococcus faecium* (VREfm) and ten as *E. faecalis* (VREfs). Irrespective of the species, *vanA* gene (89.58%) was dominant and three phenotypically vancomycin susceptible *E. faecium* isolates carried the *vanB* gene. Among virulence genes investigated, the *esp* was found in 27(71%) VREfm strains, but did not in any VREfs. Other virulence determinants were highly detected in VREfs strains. Our data indicate a high prevalence of *E. faecium* harboring vancomycin resistance with *vanA* genotype and the two VRE species displayed different virulence genes.

Keywords: *Enterococcus faecalis*, *Enterococcus faecium*, Vancomycin resistance, Virulence gene.

INTRODUCTION

Enterococci are Gram-positive intestinal commensals of humans and other animals, in addition to be an isolate from environmental sources. During the past decades an enhancement in the prevalence of enterococcal infections such as bacteremia and urinary tract infections along with emergence of multi antimicrobial resistance, particularly VRE has been reported worldwide [1, 2].

Among vancomycin-resistance phenotypes in enterococci, VanA and VanB possess highest clinical importance. Strains resistant to vancomycin and teicoplanin were assigned to

VanA phenotype while, those susceptible to teicoplanin but resistant to vancomycin were considered as the VanB phenotype [2]. The *vanA* and *vanB* gene clusters contain nine different genes for a two-component regulatory system (*vanR* and *vanS*), three resistance genes (*vanH*, encoding dehydrogenase; *vanA* or *vanB*, encoding ligase; *vanX*, encoding DD-dipeptidase); an accessory gene (*vanY*); and the *vanZ* gene, which is present in the *vanA* gene cluster whereas, the *vanW* gene is found only in the *vanB* operon. VanA is carried on Tn1546 whilst, VanB on transposons Tn1547 and Tn1549, which may be found on plasmids or inserted on the chromosome [3].

Despite the fact that *E. faecalis* has been observed as the predominant species in clinical infections, an increase in the prevalence of *E. faecium* has been seen recently [4]. This shift is likely to be explained in part by the emergence of vancomycin resistant enterococci (VRE) and *E. faecium* being the dominant detectable species among them [5].

*Address correspondence to this author at the Research Center of Infectious Diseases and Tropical Medicine, and Department of Clinical Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Tel: 0098 411 3364661; Fax: 0098 411 3364661
E-mails: hasanialka@tbzmed.ac.ir, dr.alkahasani@gmail.com

Unfortunately, little is known about the pathogenic mechanisms or virulence factors of this microorganism [6]. Enterococcal infections may occur *via* the ability to persist on harsh environments due to their intrinsic properties and even these conditions may contribute largely to emergence of this organism as a nosocomial pathogen [7, 8]. The process of invasion is usually facilitated by damage to host tissues and the presence of bacterial virulence factors such as adhesins along with antibiotic resistance that gradually assist in advancement and furtive survival in newly infected place. At the next, enterococci utilize several virulence factors for adherence and colonization in the infection site by formation of cell aggregates such as biofilms [5, 9]. At the end, interactions between host and enterococci leads to the clinical manifestation of infection in target vital tissues [5].

By consideration of the fact that the presence of putative virulence determinants among clinical isolates may promote emergence of infections and persistence of enterococci in nosocomial locations causes an increase in antibiotic resistance and act as facilities for emerging infections [10, 11], this study was designed to survey distribution of virulence genes including *asaI* (aggregation substance), *esp* (Enterococcal surface protein), *gelE* (gelatinase), *ace* (collagen adhesion) and *cpd* (sex pheromones determinant) in clinical isolates of vancomycin resistant *E. faecalis* and *E. faecium* at molecular level. To our knowledge, this is the first report from the Northwest of Iran.

MATERIALS AND METHODOLOGY

VRE Isolates and Susceptibility Tests

Thirty-eight VREfm and 10 VREfs isolates, obtained from different clinical specimens submitted in three

University teaching hospitals of Tabriz (Imam Reza and Sina Hospitals) and Orumieh (Imam Khomeini Hospital), Iran, between 2008 and 2010. The origins of isolates were as follows: urine 35 (72.91%), blood 5 (10.41%), wound 3 (6.25%), body fluids 4 (8.33%) and intravenous catheter 1 (2.08%). Initially, these isolates were identified to the species level by conventional methods described previously [12] and then, multiplex PCR was used to detect vancomycin resistant *vanA* and *vanB* genes and also to confirm phenotypic speciation by targeting D-alanine– D-alanine ligases specific for *E. faecalis* (*ddl_{E. faecalis}*) and *E. faecium* (*ddl_{E. faecium}*) as developed by Kariyama *et al.*, [13]. *E. faecalis* E206 (*vanA*⁺) and *E. faecium* E2781 (*vanB*⁺) (kindly provided by Dr. Eimaneini) was used as control strains.

For all isolates, MICs of vancomycin were determined by agar dilution method and E-test (BioMerieux, SA) according to the CLSI's (2006) guidelines [14] and manufacturer's recommendations, respectively. *E. faecalis* ATCC 29212 was used as a quality control strain on every occasion of susceptibility testing.

Detection of Virulence Genes by PCR

DNA extraction was performed by boiling method as described previously [15] and then by commercial kit (DNGTM-Plus, CinnaGen, Iran). Multiplex PCR was performed on all enterococcal isolates for the detection of virulence determinants with specific primers for each gene (Table 1) with some modification on Vankerckhoven's protocol [16]. Briefly, first 25µl master mix containing 2.5µl of bacterial suspension, 15pM of each primers for *asaI* and *gelE* and 30 pM for *esp*, 1X PCR buffer, 2.0 mM MgCl₂, 0.2 mM each deoxynucleotide triphosphate (dATP, dCTP,

Table 1. Primers used in this Study

Genes	Sequence (5' to 3')	Size(bp)	References
<i>asaI</i>	F1: GCACGCTATTACGAACTATGA R1: TAAGAAAGAACATCACCCACGA	375	[15]
<i>gelE</i>	F2: TATGACAATGCTTTTTGGGAT R2: AGATGCACCCGAAATAATATA	213	[15]
<i>esp</i>	F7: AGATTTTCATCTTTGATTCTTGG R7: AATTGATTCTTTAGCATCTGG	510	[15]
<i>cpd</i>	F8: TGGTGGGTTATTTTTCAATTC R8: TACGGCTCTGGCTTACTA	782	[29]
<i>ace</i>	F9: GGAATGACCGAGAACGATGGC R9: GCTTGATGTTGGCCTGCTTCCG	616	[14]
<i>vanA</i>	F14-CATGAATAGAATAAAAAGTTGCAATA R14-CCCCTTTAACGCTAATACGATCAA	1030	[12]
<i>vanB</i>	F15-GTGACAAACCGGAGGCGAGGA R15-CCGCCATCTCCTGCAAAAAA	433	[12]
<i>E. faecalis</i>	F16-ATCAAGTACAGTTAGTCTTTATTAG R16-ACGATTCAAAGCTAACTGAATCAGT	941	[12]
<i>E. faecium</i>	F17-TTGAGGCAGACCAGATTGACG R17-TATGACAGCGACTCCGATTCC	658	[12]

dGTP, and dTTP) and 2.5 U of *Taq* DNA polymerase (CinnaGen, Iran). The second PCR mixture contained 10 pM of each primer for *cpd* and 4pM for *ace*, 1.5 mM MgCl₂ and additional rest of reagents mentioned in first master mix. Reactions for both mixtures were done on a thermal cycler (ASTEC-Japan) with an initial denaturation at 95°C for 10 min, 30 cycles of amplification (denaturation at 94°C for 1 min, annealing at 56°C for 1 min, and extension at 72°C for 1 min), and a final extension at 72°C for 10 min.

Amplicons were analyzed on a 1.5% agarose gel and a 100-bp DNA ladder was used as the molecular size marker. The gels were stained with ethidium bromide and photographed under UV light. Each PCR assay was accompanied with a negative control, containing all of the reagents without template DNA.

Statistical Analysis

Data were analyzed statistically using chi-square test and difference was considered significant at $p < 0.05$ by SPSS software (version 18).

RESULTS

Most of VREs were isolated from intensive care units (ICUs) [16(33.3%)], nephrology [10(20.8%)] and internal [8(16.7%)] wards. Among VRE strains, thirty-five *E. faecium* harboured *vanA* gene and all of them revealed MICs ≥ 256 $\mu\text{g/ml}$, except one (MIC=8 $\mu\text{g/ml}$). Five *vanA* positive isolates did not show any studied virulence determinants. On the other hand, 3 *E. faecium* isolates carried *vanB* gene with MICs < 4 $\mu\text{g/ml}$ and also, they were negative for all virulence determinants tested. However, VREfm isolates were found with the *esp* gene (71.05%).

All *E. faecalis* showed MICs ≥ 256 $\mu\text{g/ml}$ and 8 isolates carried *vanA* gene while, in the two strains, neither *vanA* nor *vanB* gene were detected.

In comparison to *E. faecium*, vancomycin resistant *E. faecalis* strains were furnished with diverse combinations of virulence genes include: 4 strains presenting *asa1*, *gelE*, *ace* and *cpd*; 4 strains with *asa1*, *gelE* and *cpd*; 1 strain showed *gelE*, *ace* and *cpd* and another one displayed *gelE* and *cpd*. Among virulence genes studied, concomitant occurrence of *gelE* and *cpd* in all *E. faecalis* isolates was significant ($p < 0.001$). Distribution of virulence genes among vancomycin resistant *E. faecalis* and *E. faecium* are shown in Table 2.

Table 2. Distribution of Virulence Genes among Vancomycin Resistant *E. faecalis* and *E. faecium* Isolates

Virulence Genes	Vancomycin Resistant		Total (N=48)
	<i>E. faecalis</i> (N=10)	<i>E. faecium</i> (N=38)	
<i>gelE</i>	10 (100)	3 (7.89)	13 (27.08)
<i>asa1</i>	8 (80)	3 (7.89)	11 (22.91)
<i>cpd</i>	10 (100)	1 (2.63)	11 (22.91)
<i>ace</i>	5 (50)	1 (2.63)	6 (12.5)
<i>esp</i>	0 (0)	27 (71.05)	27 (56.25)

DISCUSSION

This study investigated prevalence of virulence factors in vancomycin resistant enterococci. The majority of VREs were *E. faecium* (38 out of 48 VREs). Similar enhancement in the prevalence of VRE, especially *E. faecium* has been noticed earlier in several studies from different countries [17-19]. This increase has been attributed mainly to the occurrence and spread of *vanA* and *vanB* positive VRE, which exhibited some virulence factors such as Esp (*esp*), cytolysin (*cyl*), hyaluronidase (*hyl*) [10]. In comparison among various sources of *Enterococci*, the same as clinical samples, farm animals, water and food products, isolates from clinical specimens have been attributed to have the highest virulence factors [20, 21]. In this study, *E. faecalis* and *E. faecium* strains show significantly different patterns in the incidence of virulence determinants. Similar to study of Eaton et al., (2001), in our study, all *E. faecalis* strains harbored multiple virulence determinants.

The aggregation substance is a pheromone-inducible surface protein encoded by *asa1* gene involved in adherence to eukaryotic cell [22], which may increase the hydrophobicity of the enterococcal cell surface that may delay or prevent fusion with lysosomal vesicles [23], cell aggregation and conjugation [24]. Various reports are available for the prevalence of *asa1* in enterococcal isolates obtained from different sources. In this study 8 out of 10 *E. faecalis* harbored *asa1* gene and majority (62.5%) of them were being isolated from urine specimen. Waar et al., (2002) reported high prevalence of *asa1* in *E. faecalis* isolates from liver transplant and septicemic patients and assumed that *asa1* might be associated with infection [25]. Baldassarri et al., [26] indicated presence of this gene in seven out of 11 *E. faecalis* from endocarditis, with only one strain being *vanA* positive. The present study also revealed this gene in 3 (7.89%) VREfm isolates from UTI, whereas other studies did not find *asa1* in *E. faecium* [16, 27, 28]. A much higher incidence (13%) has been reported by Elsner et al., [29] in clinical *E. faecium* isolated from blood culture. A study on food and medical isolates of enterococci showed the *asa1* gene was always associated with the presence of pheromone determinants (*cpd*, *cob*, *ccf* and *cad*) and only detected in *E. faecalis* [30]. Abriouel et al., (2008) reported high prevalence of *cpd* (89.7%) determinant in comparison of aggregation substance (58.97%) in clinical *E. faecalis* [28]. Similarly, we found the *cpd* gene in all VREfs, of them 80% were also *asa1* positive ($p < 0.001$). Meanwhile, we could find *cpd* in one VREfm, suggests that it is probably not associated with virulence in this species. The presence of sex pheromone determinant in *E. faecium* was reported earlier [31].

Gelatinase encoded by *gelE* is an extracellular metalloendopeptidase that hydrolyzes gelatin, collagen, hemoglobin, and other bioactive compounds [32]. Sabia et al., (2008) reported *gelE* gene in 19 (70%) out of 27 VRE strains; all *E. faecalis* and 5 out of 7 *E. faecium* carried the *gelE* [33]. In accordance, we detected *gelE* gene in all VREfs and 7.9% of VREfm. In fact, among virulence genes investigated, concomitant occurrence of *gelE* and *cpd* in *E. faecalis* isolates was found significant ($p < 0.001$). In contrast, some studies did not find *gelE* gene in any *E.*

faecium isolates [34] while, other researchers reported different incidence for mentioned gene in clinical isolates [11, 27]. Silent form of this gene was reported in *E. faecium* isolates [30, 35].

The *ace* gene, which codes for a putative protein with characteristics similar to a collagen-binding protein of *Staphylococcus aureus* [36] has been identified more frequently in *E. faecalis* isolates [27, 37]. Abriouel *et al.*, (2008) reported higher incidence of *ace* gene (>80%) in clinical isolates in comparison to much lower incidence or even absence in isolates obtained from vegetable foods, water and soil [28]. The present study revealed the *ace* gene in 50% of *E. faecalis* and only in one *E. faecium*. All *ace* positive isolates obtained from urine (UTI) and isolates from other sources were negative for this gene. Lebreton *et al.*, (2009) suggested that Ace may be a valuable drug target against human UTI. Low incidence or absence of the *ace* in clinical *E. faecium* have been reported in some studies [11, 27] but it is unlikely to contribute significantly to virulence.

Esp protein encoded by *esp* gene assumed to play a role in the primary surface attachment, contributing to colonization and persistence on urinary tract and biofilm formation [38, 39]. The *esp* is one of the disputed virulence elements that found on a pathogenicity island of both *E. faecalis* and *E. faecium* [40, 41].

Although, an earlier study demonstrated *esp* gene only in *E. faecalis* isolates [42] and other available data indicated that the *esp* gene was common in *E. faecalis* [15] however, a study on the food and medical isolates depicted an increasing incidence of *esp* in clinical *E. faecium* isolates than *E. faecalis* [30] and an European investigation proposed, proposed only this gene for virulence among this species [16]. Camargo *et al.*, (2006) demonstrated that *esp* (56%) was restricted to VREfm and not found in vancomycin sensitive *E. faecium* [43]. Vankerckhoven *et al.*, [16] surveyed virulence genes in European hospitals and found higher incidence of *esp* in the clinical VREfm isolates. In accordance with these investigations, in our study *esp* was the most common gene in VREfm (71.05%) but not detected in VREfs. Moreover, earlier Van Wamel *et al.*, (2007) demonstrated that Esp expression on the surface of *E. faecium*; dependent to growth condition, to vary consistently among strains and is quantitatively correlated with initial adherence and biofilm formation [44].

In the present study, three *E. faecium* isolates with *vanB* genotype were susceptible to vancomycin (MIC < 4 µg/ml) and did not carry any of examined virulence determinants. A research conducted on Australian patients with haematological disorders showed high incidence of *esp* gene in vancomycin resistant *E. faecium* (*vanB* positive), but all were negative for *asa1* and *gelE* [45].

CONCLUSION

Our data indicate a high prevalence of *E. faecium* harboring vancomycin resistance with *vanA* genotype. In addition, finding of 3 *E. faecium* with *vanB* genotype, but sensitive to vancomycin, suggest application of both phenotypic and genotypic methods for screening

VRE strains since using them in single may lead to misidentification.

VREfs possessed four distinctive patterns of virulence factors and the *gelE* gene was always associated with the presence of pheromone determinant (*cpd*) and these combinations may associate with increased virulence. Interestingly, *esp* was not found in any of VREfs strains.

On the other hand, the *esp* was the dominant determinant among *E. faecium* strains. Finding of *esp* gene in high incidence among *E. faecium*, but not in *E. faecalis*, may indicate the role of this gene in high prevalence of VREfm in hospitals environments. Although the *gelE*, *cpd*, *asa1* and *ace* genes were found in less frequencies, but there is a trend of increasing levels of virulence genes other than *esp* among *E. faecium* strains.

Meanwhile, in 8 of VREfm (3 *vanB*⁺ and five *vanA*⁺) none of these genes was present, it was concluded that other genes may be also important in the pathogenesis of VRE isolates.

However, further investigation is required to evaluate the association of these virulent determinants with occurrence of an infection by VREs in more number of isolates.

CONFLICT OF INTERESTS

Declared none.

ABBREVIATIONS

Ace	=	Collagen binding protein
Asa1	=	Aggregation substance
ATCC	=	American type culture collection
CLSI	=	Cinical and Laboratory Standards Institute
Esp	=	Enterococcal surface protein
GelE	=	Gelatinase
MICs	=	Minimum inhibitory concentrations
Min	=	Minutes
VanA	=	D- Ala- D- Lac ligase
vanB	=	D- Ala- D- Lac ligase
VRE	=	Vancomycin resistant Enterococci
VREfm	=	Vancomycin resistant <i>Enterococcus faecium</i>
VREfs	=	Vancomycin resistant <i>Enterococcus faecalis</i>

ACKNOWLEDGMENT

This work was supported by Research Center of Infectious Diseases and Tropical Medicine (grant No.89/3), Tabriz University of Medical Sciences, Tabriz, Iran. We wish to thank Dr. Eimaneini, for providing the *vanA* and *vanB* positive isolates. In addition, we are grateful to Ms. Mitra Nojavan and Ms. Leila Deighani for their assistance in specimen collection and Mr. Ahad Bazmani for his laboratory support in research center.

This work has been done as part of Ph.D thesis (No. 88/4- 4/5) of first author.

REFERENCES

- [1] Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clin Infect Dis* 2001; 32(suppl 2): 133-45.
- [2] Cetinkay Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. *Clin Microbiol Rev* 2000; 13: 686-707.
- [3] Courvalin P. Vancomycin resistance in gram-positive cocci. *Clin Infect Dis* 2006; 42: S25-S34.
- [4] Fisher K, Phillips C. The ecology, epidemiology and virulence of *Enterococcus*. *Microbiology* 2009; 155: 1749-57.
- [5] Mundy L, Sahm D, Gilmore M. Relationships between enterococcal virulence and antimicrobial resistance. *Clin Microbiol Rev* 2000; 13: 513-22.
- [6] Mascini E, Bonten M. Vancomycin resistant enterococci: consequences for therapy and infection control. *Clin Microbiol Infect* 2005; 11: 43-56.
- [7] Kearns A, Freeman R, Lightfoot N. Nosocomial enterococci: resistance to heat and sodium hypochlorite. *J Hosp Infect* 1995; 30: 193-9.
- [8] Neely AN, Maley MP. Survival of enterococci and staphylococci on hospital fabrics and plastic. *J Clin Microbiol* 2000; 38: 724-26.
- [9] Kayaoglu G, Ørstavik D. Virulence factors of *Enterococcus faecalis*: relationship to endodontic disease. *Crit Rev Oral Biol Med* 2004; 15: 308-20.
- [10] Klare I, Konstabel C, Mueller-Bertling S, et al. Spread of ampicillin/vancomycin-resistant *Enterococcus faecium* of the epidemic-virulent clonal complex-17 carrying the genes *esp* and *hyl* in German hospitals. *Eur Clin Microbiol Infect Dis* 2005; 24: 815-25.
- [11] Billstrom H, Lund B, Sullivan A, Nord CE. Virulence and antimicrobial resistance in clinical *Enterococcus faecium*. *Int J Antimicrob Agents* 2008; 3: 374-7.
- [12] Manero A, Blanch AR. Identification of *Enterococcus* spp. with a biochemical key. *Appl Environ Microbiol* 1999; 65: 4425-30.
- [13] Kariyama R, Mitsuhashi R, Chow JW, Clewell DB, Kumon H. Simple and reliable multiplex PCR assay for surveillance isolates of vancomycin-resistant enterococci. *J Clin Microbiol* 2000; 38: 3092-5.
- [14] CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 16th ed, Informational Supplement M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute 2006.
- [15] Creti R, Imperi M, Bertuccini L, et al. Survey for virulence determinants among *Enterococcus faecalis* isolated from different sources. *J Med Microbiol* 2004; 53: 13-20.
- [16] Vankerckhoven V, Van Autgaerden T, Vael C, et al. Development of a multiplex PCR for the detection of *asa1*, *gelE*, *cylA*, *esp*, and *hyl* genes in enterococci and survey for virulence determinants among European hospital isolates of *Enterococcus faecium*. *J Clin Microbiol* 2004; 42: 4473-9.
- [17] Willems RJJ, Bonten MJM. Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity. *Curr Opin Infect Dis* 2007; 20: 384-90.
- [18] Bonadio M, Meini M, Tagliaferri E, Gigli C, Vigna A. Enterococcal glycopeptide resistance at an Italian teaching hospital. *J Antimicrob Chemother* 2000; 46: 129-31.
- [19] Emameini M, Aligholi M, Aminshahi M. Characterization of glycopeptides, aminoglycosides and macrolide resistance among *Enterococcus faecalis* and *Enterococcus faecium* isolates from hospitals in Tehran. *Polish J Microbiol* 2008; 57: 173-8.
- [20] Busani L, Grosso MD, Paladini C, et al. Antimicrobial susceptibility of vancomycin-susceptible and-resistant enterococci isolated in Italy from raw meat products, farm animals, and human infections. *Int J Food Microbiol* 2004; 97: 17-22.
- [21] Mannu L, Paba A, Daga E, et al. Comparison of the incidence of virulence determinants and antibiotic resistance between *Enterococcus faecium* strains of dairy, animal and clinical origin. *Int J Food Microbiol* 2003; 88: 291-304.
- [22] Galli D, Lottspeich F, Wirth R. Sequence analysis of *Enterococcus faecalis* aggregation substance encoded by the sex pheromone plasmid pAD1. *Mol Microbiol* 1990; 4: 895-904.
- [23] Eaton TJ, Gasson MJ. A variant enterococcal surface protein Espfm in *Enterococcus faecium*; distribution among food, commensal, medical, and environmental isolates. *FEMS Microbiol Lett* 2002; 216: 269-75.
- [24] Koch S, Hufnagel M, Theilacker C, Huebner J. Enterococcal infections: host response, therapeutic, and prophylactic possibilities. *Vaccine* 2004; 22: 822-30.
- [25] Waar K, Muscholl-Silberhorn AB, Willems RJJ, Slooff MJH, Harmen HJM, Degener JE. Genogrouping and incidence of virulence factors of *Enterococcus faecalis* in liver transplant patients differ from blood culture and fecal isolates. *J Infect Dis* 2002; 185: 1121-7.
- [26] Baldassarri L, Creti R, Arciola C, Montanaro L, Venditti M, Di Rosa R. Analysis of virulence factors in cases of enterococcal endocarditis. *Clin Microbiol Infect* 2004; 10: 1006-8.
- [27] Valenzuela AS, Omar NB, Abriouel H, et al. Risk factors in enterococci isolated from foods in Morocco: Determination of antimicrobial resistance and incidence of virulence traits. *Food Chem Toxicol* 2008; 46: 2648-52.
- [28] Abriouel H, Omar NB, Molinos AC, et al. Comparative analysis of genetic diversity and incidence of virulence factors and antibiotic resistance among enterococcal populations from raw fruit and vegetable foods, water and soil, and clinical samples. *Int J Food Microbiol* 2008; 123: 38-49.
- [29] Elsner HA, Sobottka I, Mack D, Claussen M, Laufs R, Wirth R. Virulence factors of *Enterococcus faecalis* and *Enterococcus faecium* blood culture isolates. *Eur J Clin Microbiol Infect Dis* 2000; 19: 39-42.
- [30] Eaton TJ, Gasson MJ. Molecular screening of *Enterococcus* virulence determinants and potential for genetic exchange between food and medical isolates. *Appl Environ Microbiol* 2001; 67: 1628-35.
- [31] Heaton MP, Discotto LF, Pucci MJ, Handwerker S. Mobilization of vancomycin resistance by transposon-mediated fusion of a VanA plasmid with an *Enterococcus faecium* sex pheromone-response plasmid. *Gene* 1996; 171: 9-17.
- [32] Su Y, Sulavik M, He P, et al. Nucleotide sequence of the gelatinase gene (*gelE*) from *Enterococcus faecalis* subsp. *liquefaciens*. *Infect Immun* 1991; 59: 415-20.
- [33] Sabia C, De Niederhäusern S, Guerrieri E, et al. Detection of bacteriocin production and virulence traits in vancomycin resistant enterococci of different sources. *J Appl Microbiol* 2008; 104: 970-9.
- [34] Vankerckhoven V, Huys G, Vancanneyt M, et al. Genotypic diversity, antimicrobial resistance and virulence factors of human isolates and probiotic cultures constituting two intraspecific groups in *Enterococcus faecium*. *Appl Environ Microbiol* 2008; 74: 4247-55.
- [35] Biavasco F, Foglia G, Paoletti C, et al. VanA-type Enterococci from humans, animals and food: Species distribution, population structure, Tn1546-typing and location, and virulence determinants. *Appl Environ Microbiol* 2007; 73: 3307-19.
- [36] Nallapareddy SR, Singh KV, Duh RW, Weinstock GM, Murray BE. Diversity of ace, a gene encoding a microbial surface component recognizing adhesive matrix molecules, from different strains of *Enterococcus faecalis* and evidence for production of Ace during human infections. *Infect Immun* 2000; 68: 5210-7.
- [37] Cariolato D, Andrighetto C, Lombardi A. Occurrence of virulence factors and antibiotic resistances in *Enterococcus faecalis* and *Enterococcus faecium* collected from dairy and human samples in North Italy. *Food Control* 2008; 19: 886-92.
- [38] Toledo-Arana A, Valle J, Solano C, et al. The enterococcal surface protein, Esp, is involved in *Enterococcus faecalis* biofilm formation. *Appl Environ Microbiol* 2001; 67: 4538-45.
- [39] Shankar N, Lockatell C, Baghdayan AS, Drachenberg C, Gilmore MS, Johnson DE. Role of *Enterococcus faecalis* surface protein Esp in the pathogenesis of ascending urinary tract infection. *Infect Immun* 2001; 69: 4366-72.
- [40] Leavis H, Top J, Shankar N, et al. A novel putative enterococcal pathogenicity island linked to the *esp* virulence gene of *Enterococcus faecium* and associated with epidemicity. *J Bacteriol* 2004; 186: 672-82.
- [41] Shankar N, Baghdayan AS, Gilmore MS. Modulation of virulence within a pathogenicity island in vancomycin-resistant *Enterococcus faecalis*. *Nature* 2002; 417: 746-50.
- [42] Shankar V, Baghdayan AS, Huycke MM, Lindahl G, Gilmore MS. Infection-derived *Enterococcus faecalis* strains are enriched in *esp*, a gene encoding a novel surface protein. *Infect Immun* 1999; 67: 193-200.
- [43] Camargo I, Gilmore M, Darini A. Multilocus sequence typing and analysis of putative virulence factors in vancomycin resistant and

- vancomycin sensitive *Enterococcus faecium* isolates from Brazil. Clin Microbiol Infect 2006; 12: 1123-30.
- [44] Van Wamel WJB, Hendrickx APA, Bonten MJM, *et al.* Growth condition-dependent Esp expression by *Enterococcus faecium* affects initial adherence and biofilm formation. Infect Immun 2007; 75: 924-31.
- [45] Worth L, Slavin M, Vankerckhoven V, Goossens H, Grabsch E, Thursky K. Virulence determinants in vancomycin-resistant *Enterococcus faecium* vanB: clonal distribution, prevalence and significance of esp and hyl in Australian patients with haematological disorders. J Hosp Infect 2008; 68: 137-44.

Received: August 29, 2011

Revised: September 23, 2011

Accepted: December 02, 2011

© Sharifi *et al.*; Licensee Bentham Open.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.